Immunoglobulin-mediated membranoproliferative glomerulonephritis

MONDO:0014005

Glomerulonephritis characterized by mesangial proliferation, endocapillary proliferation, and glomerular capillary wall remodeling with immune complex deposits from classical complement pathway activation.

Also known as: Ig-mediated MPGN, Ig-mediated membranoproliferative glomerulonephritis, NPHS7, immune complex mediated membranoproliferative glomerulonephritis, immunoglobulin-mediated MPGN, immunoglobulin-mediated membranoproliferative glomerulonephritis, membranoproliferative glomerulonephritis type I, mesangiocapillary glomerulonephritis type 1

19 clinical trials for this condition and its sub-types, 12 tagged with Immunoglobulin-mediated membranoproliferative glomerulonephritis itself.

Follow this condition to get notified about new trials

Where it sits in the disease tree

Browse by category →

Part of

↑ Hereditary nephritis (152) ↑ Primary membranoproliferative glomerulonephritis (26) ↑ Familial nephrotic syndrome (22)

Including sub-types (19) Tagged with Immunoglobulin-mediated membranoproliferative glomerulonephritis (12)

Trials to join now! 5 Not yet recruiting 1 Not yet finished but already full! 4 Completed 2

Can a gene-silencing drug calm overactive complement in kidney disease?

Disease control Not yet recruiting

This phase II trial tests an experimental drug called QLS7305 in people with several kidney diseases driven by overactivation of the complement system, a part of the immune system. The drug is a small interfering RNA (siRNA) designed to reduce production of complement protein C3,…

Phase 2 • Sponsor: Qilu Pharmaceutical Co., Ltd. • Aim: Disease control

Last updated Jul 30, 2026 00:00 UTC

Immunoglobulin-mediated membranoproliferative glomerulonephritis

Where it sits in the disease tree

Can a gene-silencing drug calm overactive complement in kidney disease?